Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors

被引：2
|
作者：
Choi, Bae Jung
Devalingam, Devalingam
Alistar, Angela
El-Khoueiry, Anthony
Mita, Alain
Kang, Hwankyu
Choi, Jinho
Ahn, Hyunji
Kim, Jeongjun
Lee, Seung-Joo
Yang, Yeong-In
Ahn, Jiye
Jeon, Borami
Kim, Jaeseung
Nam, Kiyean
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2255
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Raoul Tibes
    Gil Fine
    Gavin Choy
    Sanjeev Redkar
    Pietro Taverna
    Aram Oganesian
    Amarpal Sahai
    Mohammad Azab
    Anthony W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 463 - 471
  • [32] Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
    Sun, Yongkun
    Yang, Lin
    Hao, Xuezhi
    Liu, Yutao
    Zhang, Jinwen
    Ning, Zhiqiang
    Shi, Yuankai
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [33] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    Hollebecque, A.
    Deutsch, E.
    Massard, C.
    Gomez-Roca, C.
    Bahleda, R.
    Ribrag, V.
    Bourgier, C.
    Lazar, V.
    Lacroix, L.
    Gazzah, A.
    Varga, A.
    de Baere, T.
    Beier, F.
    Kroesser, S.
    Trang, K.
    Zenke, F. T.
    Klevesath, M.
    Soria, Jean-Charles
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1530 - 1538
  • [34] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey A.
    Pavlick, Anna
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 47 - 58
  • [35] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [36] Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors
    Kaneda, H.
    Okamoto, I.
    Satoh, T.
    Arao, T.
    Nishio, K.
    Sarashina, A.
    Konishi, K.
    Stopfer, P.
    Kaiser, R.
    Nakagawa, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 133 - 133
  • [37] Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
    Li, Huiping
    Liu, Rongrui
    Shao, Bin
    Ran, Ran
    Song, Guohong
    Wang, Ke
    Shi, Yehui
    Liu, Jihong
    Hu, Wenjing
    Chen, Fu
    Liu, Xiaoran
    Zhang, Gairong
    Zhao, Chuanhua
    Jia, Ru
    Wang, Quanren
    Rugo, Hope S.
    Zhang, Yifan
    Li, Guangze
    Xu, Jianming
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 370 - +
  • [38] Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
    Yongkun Sun
    Lin Yang
    Xuezhi Hao
    Yutao Liu
    Jinwen Zhang
    Zhiqiang Ning
    Yuankai Shi
    Journal of Hematology & Oncology, 12
  • [39] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Alex A. Adjei
    Patricia LoRusso
    Antoni Ribas
    Jeffrey A. Sosman
    Anna Pavlick
    Grace K. Dy
    Xiaofei Zhou
    Esha Gangolli
    Michelle Kneissl
    Stephanie Faucette
    Rachel Neuwirth
    Viviana Bózon
    Investigational New Drugs, 2017, 35 : 47 - 58
  • [40] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    A. Hollebecque
    E. Deutsch
    C. Massard
    C. Gomez-Roca
    R. Bahleda
    V. Ribrag
    C. Bourgier
    V. Lazar
    L. Lacroix
    A. Gazzah
    A. Varga
    T. de Baere
    F. Beier
    S. Kroesser
    K. Trang
    F. T. Zenke
    M. Klevesath
    Jean-Charles Soria
    Investigational New Drugs, 2013, 31 : 1530 - 1538
12345